HC Wainwright & Co. Reiterates Buy on IO Biotech, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on IO Biotech (NASDAQ:IOBT) and maintained an $8 price target.
September 13, 2023 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on IO Biotech, maintaining an $8 price target.
The reiteration of a 'Buy' rating and maintenance of an $8 price target by HC Wainwright & Co. indicates a positive outlook for IO Biotech. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100